← All trials
NCT05725512
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Jan 1, 2027
- Completion date
- Jul 1, 2027
- First posted
- Feb 13, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 490
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- Maastricht UniversityCollaborator
- Maastricht UniversityCollaborator
- Jeroen Bosch ZiekenhuisCollaborator
- Medical Center HaaglandenCollaborator
- Onze Lieve Vrouw HospitalCollaborator
- Radboud UniversityCollaborator
- University of GroningenCollaborator
- Leiden UniversityReponsible party - principal investigator
- University of AmsterdamCollaborator
- Amphia Hospital Breda, the NetherlandsCollaborator
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.